Hyalart D (Sodium Hyaluronate)

Hyalart D is indicated for the symptomatic management of osteoarthritis in joints where conservative therapies have been insufficient.

• Osteoarthritis of the knee, providing intra‑articular supplementation to improve joint lubrication.
• Osteoarthritis of the hip, used when pain persists despite standard analgesics.
• Osteoarthritis of the ankle or other peripheral joints, administered to enhance synovial fluid viscosity.
• Adjunctive therapy in patients awaiting joint replacement surgery, aiming to delay the procedure.

• Sodium hyaluronate in Hyalart D mimics the natural hyaluronic acid component of synovial fluid. After intra‑articular injection, it integrates into the joint space, increasing the viscoelastic properties of the fluid. This enhanced lubrication reduces mechanical wear, improves shock absorption, and may modulate inflammatory pathways by decreasing cytokine activity and limiting cartilage degradation. The overall effect supports joint mobility and reduces pain perception.

Adverse reactions to Hyalart D are generally localized to the injection site, though systemic events can occur rarely.

Common

• Transient pain or swelling at the injection site.
• Mild warmth or flushing in the treated joint.
• Temporary stiffness or reduced range of motion.
• Low‑grade fever or malaise within 24 hours.

Serious

• Acute joint infection (septic arthritis) requiring medical intervention.
• Allergic hypersensitivity reaction, including rash, urticaria, or anaphylaxis.
• Persistent joint effusion or severe inflammation.
• Nerve injury or vascular compromise at the injection site.

Before administering Hyalart D, clinicians should evaluate patient history and joint condition to minimize risks.

• Confirm absence of active joint infection or skin lesions over the injection site.
• Assess for known hypersensitivity to hyaluronic acid or any component of the formulation.
• Use caution in patients with severe knee malalignment or mechanical instability.
• Avoid use in patients with uncontrolled coagulopathy or on anticoagulant therapy without appropriate monitoring.
• Consider postponing treatment during pregnancy or lactation until safety data are available.
• Evaluate renal function in patients with severe systemic disease, as clearance may be altered.
• Ensure aseptic technique and proper imaging guidance for accurate intra‑articular placement.

Hyalart D may interact with other agents that affect joint health or infection risk.

Avoid

• Concurrent intra‑articular corticosteroid injections within 2 weeks of Hyalart D administration.
• Use with intra‑articular antibiotics or other viscosupplements in the same joint during the same treatment cycle.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to increased bleeding risk at the injection site.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask early signs of infection.
• Disease‑modifying osteoarthritis drugs (DMOADs) where combined effects on cartilage are not fully established.
• Immunosuppressive therapies that could predispose to joint infection.